INTERLEUKIN-10 PRETREATMENT PROTECTS TARGET-CELLS FROM TUMOR-SPECIFIC AND ALLO-SPECIFIC CYTOTOXIC T-CELLS AND DOWN-REGULATES HLA CLASS-I EXPRESSION

被引:281
作者
MATSUDA, M
SALAZAR, F
PETERSSON, M
MASUCCI, G
HANSSON, J
PISA, P
ZHANG, QJ
MASUCCI, MG
KIESSLING, R
机构
[1] KAROLINSKA HOSP, DEPT MED, S-17176 STOCKHOLM, SWEDEN
[2] RADIUMHEMMET, DEPT ONCOL, STOCKHOLM, SWEDEN
[3] YAMANASHI MED COLL, DEPT SURG, YAMANASHI 40938, JAPAN
关键词
D O I
10.1084/jem.180.6.2371
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interleukin 10 (IL-10) is a cytokine with a variety of reported effects including inhibition of monocyte major histocompatibility complex (MHC) class II-dependent antigen presentation, type 1 helper T cell cytokine production, and inhibition of T cell proliferation. Herein we report the effect of IL-10 pretreatment on antigen presentation to tumor- and allo-specific CD8(+) cytotoxic T lymphocytes (CTL). Prior incubation of human melanoma cells with recombinant IL-10 (rIL-10) for 48-72 h resulted in a dose-dependent, up to 100% inhibition, of autologous CTL-mediated, HLA-A2.1-restricted, tumor-specific lysis. Allo-specific CTL cytotoxicity against Epstein-Barr virus-transformed lymphoblastoid cell lines (LCL) was also inhibited, demonstrating a protective effect also on lymphoid cells. In contrast, IL-10 pretreatment of allogeneic LCL or K562 targets had either no effect or slightly enhanced cytotoxic activity mediated by freshly isolated or IL-2-activated natural killer cells. Flow cytometric analysis with monoclonal antibodies against HLA-A2, or nonpolymorphic determinants of MHC class I proteins, revealed a 20-50% reduction in cell-surface expression, whereas intercellular adhesion molecules 1, and 2, and lymphocyte function-associated antigen 3 levels were not affected. In addition, relative to untreated target cells, IL-10 pretreated tumor cells were unaltered in their capacity to affect CTL-mediated lysis by cold target inhibition, demonstrating that the effect of IL-10 is unrelated to the initial binding of CTL to their targets. These results are compatible with an effect of IL-10 on the MHC class I antigen presentation pathway, and suggest a novel mechanism of immune tolerance, based on escape from CTL-mediated tumor and allo-transplant rejection.
引用
收藏
页码:2371 / 2376
页数:6
相关论文
共 22 条
[1]   HIGH-LEVELS OF INTERLEUKIN-10 PRODUCTION IN-VIVO ARE ASSOCIATED WITH TOLERANCE IN SCID PATIENTS TRANSPLANTED WITH HLA MISMATCHED HEMATOPOIETIC STEM-CELLS [J].
BACCHETTA, R ;
BIGLER, M ;
TOURAINE, JL ;
PARKMAN, R ;
TOVO, PA ;
ABRAMS, J ;
MALEFYT, RD ;
DEVRIES, JE ;
RONCAROLO, MG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (02) :493-502
[2]   LOSS OF TRANSPORTER PROTEIN, ENCODED BY THE TAP-1 GENE, IS HIGHLY CORRELATED WITH LOSS OF HLA EXPRESSION IN CERVICAL CARCINOMAS [J].
CROMME, FV ;
AIREY, J ;
HEEMELS, MT ;
PLOEGH, HL ;
KEATING, PJ ;
STERN, PL ;
MEIJER, CJLM ;
WALBOOMERS, JMM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (01) :335-340
[3]  
DEWAALMALEFYT R, 1991, J EXP MED, V174, P915
[4]  
DING L, 1993, J IMMUNOL, V151, P1224
[5]   2 TYPES OF MOUSE T-HELPER CELL .4. TH2 CLONES SECRETE A FACTOR THAT INHIBITS CYTOKINE PRODUCTION BY TH1 CLONES [J].
FIORENTINO, DF ;
BOND, MW ;
MOSMANN, TR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (06) :2081-2095
[6]  
FIORENTINO DF, 1991, J IMMUNOL, V146, P3444
[7]   INTERLEUKIN-10 PRODUCTION BY HUMAN CARCINOMA CELL-LINES AND ITS RELATIONSHIP TO INTERLEUKIN-6 EXPRESSION [J].
GASTL, GA ;
ABRAMS, JS ;
NANUS, DM ;
OOSTERKAMP, R ;
SILVER, J ;
LIU, F ;
CHEN, M ;
ALBINO, AP ;
BANDER, NH .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (01) :96-101
[8]  
GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792
[9]   INTERLEUKIN-10, A NOVEL B-CELL STIMULATORY FACTOR - UNRESPONSIVENESS OF X-CHROMOSOME LINKED IMMUNODEFICIENCY-B CELLS [J].
GO, NF ;
CASTLE, BE ;
BARRETT, R ;
KASTELEIN, R ;
DANG, W ;
MOSMANN, TR ;
MOORE, KW ;
HOWARD, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (06) :1625-1631
[10]   PRESENCE OF INTERLEUKIN 10 (IL-10) IN THE ASCITES OF PATIENTS WITH OVARIAN AND OTHER INTRAABDOMINAL CANCERS [J].
GOTLIEB, WH ;
ABRAMS, JS ;
WATSON, JM ;
VELU, TJ ;
BEREK, JS ;
MARTINEZMAZA, O .
CYTOKINE, 1992, 4 (05) :385-390